Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
IMPORTANT NOTE: This activity is not accredited for CME/CE credit.
Jointly provided by
Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.
Release date: 8/15/2024
Expiration date: 8/15/2026
Estimated time to complete: 1.0 hour
Overview
This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).
The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Faculty
Saad Usmani, MD, MBA, FACP, FASCO—Program Chair
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
Director of Myeloma: Blavatnik Family – Chelsea Medical Center at Mount Sinai
New York, New York
Ashley Steinberger, APP
Nurse Practitioner
Memorial Sloan Kettering Cancer Center
New York, New York
Target Audience
This activity has been designed to meet the educational needs of community hematologist-oncologists and other health care providers involved in the care of RRMM patients.
Learning Objectives
After completing this activity, participants should be better able to:
- Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
- Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
- Employ the recommended strategies to monitor for treatment complications and manage AEs associated with bispecific antibody therapy
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information
For questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.
Privacy Policy
This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.
Copyright
© 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.